NEW YORK (GenomeWeb News) – In the latter half of 2013, Bio-Rad Laboratories accrued $35 million in costs associated with its initial efforts to resolve investigations into violations of federal anti-bribery laws, the company said in its Form 10-K this week. The company had previously said that in 2010 it disclosed to the US Department of Justice and the US Securities and Exchange Commission that conduct by certain of its overseas operations may have violated the anti-bribery provisions of the US Foreign Corrupt Practices Act.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: map of human protein interactions, mutant phenotype variability in organisms of the same species from different genetic backgrounds, and more.

Critics call the Fred Hutchinson Cancer Research Center's Gary Gilliland's prediction of cancer cures within 10 years "out of touch with reality" and "irresponsible."

Ivan Oransky discusses the need for reproducibility research at The Conversation.

The San Diego Union-Tribune posts videos from Biocom's Speaker Series with Illumina's Jay Flatley, who discusses Roche's failed hostile takeover bid.